€1.1m+ · Pre-Seed · Healthtech · Espoo, Finland
Cornea Sense has completed a €1.1m+ Pre-Seed financing combining private investment with a Business Finland R&D grant. The company's funding update names Innovestor Angel CoFund and angels including eye surgeon Matts Linder and Kinled Holding chairman Patrick Aisher. The capital will support clinical validation, the regulatory path for a Class IIa medical device, device miniaturisation and production design.
Measuring water instead of estimating it
Eye clinics currently infer corneal hydration through measurements such as thickness, cell counts and tomography. Those tools can indicate swelling or structural change, but they do not directly measure the amount of water in the cornea. Cornea Sense is developing a non-contact device that combines optical coherence tomography with terahertz sensing to produce a layer-by-layer hydration reading in under a minute.
That measurement could add information to decisions around cataract and refractive surgery, follow-up after procedures, dry-eye treatment and research into conditions including glaucoma, keratoconus and diabetes. The company is careful to describe several of these as uses it is still exploring, rather than established clinical claims.
A familiar workflow lowers one adoption barrier
Cornea Sense's commercial proposition depends on making a new measurement fit an eye exam that clinicians already understand. OCT is standard equipment in many clinics, so pairing its familiar imaging workflow with water-sensitive sensing may be easier to adopt than introducing a separate, lengthy procedure. A reading that takes less than a minute could also make repeat measurements practical before and after treatment.
The harder milestones are clinical and regulatory. The Aalto University spinout says it has more than ten peer-reviewed publications, a PCT patent application and a functional prototype validated on phantom models. The financing is meant to move from that research base towards measurements on human eyes and pilot sites in Europe and the US.
That transition will determine whether direct hydration data changes a clinical decision often enough to justify another diagnostic device. Miniaturisation and production design can reduce deployment friction, but the product still needs evidence that its reading is reliable, interpretable and useful alongside established tests. The round gives Cornea Sense resources to turn a technically distinct signal into a repeatable clinical workflow.
Sources checked:
Cornea Sense company and funding update · Dealroom funding report · Tech.eu Funding Explorer
